Physics:Deuruxolitinib
Deuruxolitinib, sold under the brand name Leqselvi, is a medication used for the treatment of alopecia areata.[1] It is a Janus kinase inhibitor selective for JAK1 and JAK2.[2] Although the relative effectiveness of deuruxolitinib and another Janus kinase inhibitor—baricitinib—for alopecia areata may vary depending on the population studied, both drugs are more effective than alternative treatments.[3]
Deuruxolitinib was approved for medical use in the United States in July 2024.[4][5][6]
Medical uses
Deuruxolitinib is indicated for the treatment of adults with severe alopecia areata.[1]
Side effects
The FDA prescribing label for deuruxolitinib contains a boxed warning for serious infections; malignancies; cardiovascular death, myocardial infarction, and stroke; and thrombosis.[1]
Society and culture
Legal status
Deuruxolitinib was approved for medical use in the United States in July 2024.[4][5][7]
Names
Deuruxolitinib is the international nonproprietary name[8] and the United States Adopted Name.[9]
References
- ↑ 1.0 1.1 1.2 Cite error: Invalid
<ref>tag; no text was provided for refs namedLeqselvi FDA label - ↑ King, Brett; Mesinkovska, Natasha; Mirmirani, Paradi; Bruce, Suzanne; Kempers, Steve; Guttman-Yassky, Emma; Roberts, Janet L.; McMichael, Amy et al. (August 2022). "Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata". Journal of the American Academy of Dermatology 87 (2): 306–313. doi:10.1016/j.jaad.2022.03.045. ISSN 1097-6787. PMID 35364216.
- ↑ SEDEH, Farnam Barati; MICHAELSDÓTTIR, Thorunn Elísabet; HENNING, Mattias Arvid Simon; JEMEC, Gregor Borut Ernst; IBLER, Kristina Sophie (25 January 2023). "Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis". Acta Dermato-Venereologica 103: 4536. doi:10.2340/actadv.v103.4536. ISSN 0001-5555. PMID 36695751.
- ↑ 4.0 4.1 "Leqselvi approval letter". https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217900Orig1s000ltr.pdf.
- ↑ 5.0 5.1 "Novel Drug Approvals for 2024". 1 October 2024. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024.
- ↑ (PDF) New Drug Therapy Approvals 2024 (Report). January 2025. https://www.fda.gov/media/184967/download. Retrieved 21 January 2025.
- ↑ "U.S. FDA Approves Leqselvi (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata" (Press release). Sun Pharmaceutical. 25 July 2024. Archived from the original on 26 July 2024. Retrieved 26 July 2024 – via PR Newswire.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 86". WHO Drug Information 35 (3). 2021.
- ↑ "Deuruxolitinib". https://searchusan.ama-assn.org/finder/usan/search/GH-186/relevant/1/.
Further reading
- "Inhibition of T-cell activity in alopecia areata: recent developments and new directions". Frontiers in Immunology 14. 2023. doi:10.3389/fimmu.2023.1243556. PMID 38022501.
External links
- "Deuruxolitinib (Code C175770)". https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C175770.
- "Deuruxolitinib Phosphate (Code C175771)". https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C175771.
- Clinical trial number NCT04518995 for "Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) (THRIVE-AA1)" at ClinicalTrials.gov
- Clinical trial number NCT04797650 for "Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) (THRIVE-AA2)" at ClinicalTrials.gov
 |  |
